QuidelOrtho Corporation Reports Q4 2025 Earnings Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy QDEL?
Source: seekingalpha
- Strong Financial Performance: QuidelOrtho reported Q4 2025 revenue of $724 million, reflecting a 2% year-over-year increase despite declines in COVID and donor screening revenues, with non-respiratory business growing by 7%, showcasing the company's success in diversifying its revenue streams.
- Significant Cost Savings: CEO Brian Blaser highlighted the achievement of $140 million in cost savings and an increase in adjusted EBITDA margins to the low 20s, which not only enhances the company's financial stability but also provides funding for future investments.
- Accelerated R&D Transformation: The company has made significant upgrades in R&D, securing FDA clearances for the high-sensitivity troponin eye assay and the ID MTS Direct Antiglobulin Test Card, indicating ongoing innovation in its product pipeline that supports long-term growth.
- Optimistic 2026 Outlook: CFO Busky's guidance for 2026 indicates expected revenues between $2.7 billion and $2.9 billion, with adjusted EBITDA anticipated between $630 million and $670 million, reflecting the company's confidence in future growth, particularly in the sustained expansion of its Labs business.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QDEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QDEL
Wall Street analysts forecast QDEL stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 23.735
Low
35.00
Averages
35.00
High
35.00
Current: 23.735
Low
35.00
Averages
35.00
High
35.00
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QuidelOrtho Signs Strategic Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has signed a long-term supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitive position in the market.
- Market Expansion Initiative: This agreement will accelerate customer access to high-quality, scalable, and cost-effective solutions in select international markets outside the United States, addressing global demand.
- Product Diversification: By adding new analytical platforms and assay menus, QuidelOrtho will better serve key international markets, enhancing the adaptability of its products.
- Long-term Strategic Positioning: This collaboration not only strengthens QuidelOrtho's global market presence but also lays the groundwork for future growth, expected to drive the company's further development in international markets.
See More
QuidelOrtho Partners with Lifotronic for Global Expansion
- Strategic Partnership: QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitiveness in international markets.
- Market Expansion Initiative: This agreement aims to accelerate customer access to scalable, high-quality, and cost-effective solutions outside the United States, which is expected to significantly increase the company's market penetration globally.
- Product Portfolio Enhancement: By collaborating with Lifotronic, QuidelOrtho will be able to add new analytical platforms and assay menus, catering to diverse market needs and thereby enhancing product diversity and market adaptability.
- International Market Strategy: This partnership not only reinforces QuidelOrtho's global strategy but also aims to drive business growth in key international markets, thereby increasing the company's influence in the global medical testing sector.
See More
QuidelOrtho Enters Strategic Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has signed a long-term strategic supply agreement with Lifotronic to expand its global immunoassay portfolio, introducing new analyzer platforms to enhance market competitiveness.
- Market Expansion Initiative: This agreement will accelerate QuidelOrtho's customer access in key international markets outside the U.S., providing high-quality, cost-effective solutions to meet the growing global demand for testing.
- Portfolio Enrichment: By adding new analyzer platforms and expanding the assay menu, QuidelOrtho will be able to offer a broader range of testing options, thereby enhancing its service capabilities and customer satisfaction in the global market.
- Long-term Strategic Implications: This collaboration not only aids QuidelOrtho's positioning in international markets but also strengthens its leadership in the global immunodiagnostics sector, further solidifying its market share.
See More
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitive position in the market.
- International Market Expansion: This agreement will accelerate QuidelOrtho's customer access outside the United States, ensuring the provision of scalable, high-quality, and cost-effective solutions to meet the growing global demand for testing.
- Product Portfolio Enhancement: Through collaboration with Lifotronic, QuidelOrtho will introduce new analyzer platforms and assay menus, further increasing its product diversity and service capabilities in international markets.
- Market Influence Growth: This initiative not only aids QuidelOrtho in penetrating key international markets but also enhances its market share and brand influence in the global immunodiagnostics sector.
See More
QuidelOrtho Enters Long-Term Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has signed a long-term supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitive position in the market.
- Market Expansion Initiative: This agreement will accelerate QuidelOrtho's customer access in markets outside the U.S., providing high-quality, scalable, and cost-effective solutions to meet global demand.
- Product Line Enhancement: By collaborating with Lifotronic, QuidelOrtho will introduce new analytical platforms, further increasing its product diversity and technological edge in international markets.
- Future Growth Potential: This move not only helps boost QuidelOrtho's market share but also lays the groundwork for long-term growth in the global immunoassay sector, reflecting the company's commitment to international markets.
See More
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic to expand its global immunoassay portfolio, aiming to accelerate customer access to high-quality, cost-effective solutions in international markets.
- New Assay Additions: The collaboration is expected to add over 25 new assays to QuidelOrtho's menu, enhancing its competitiveness in international tenders and catering to diverse needs from small laboratories to large high-throughput environments.
- Market Expansion Focus: The commercial focus of the agreement will be on multiple regions including Europe, the Middle East, Africa, and Asia-Pacific, supporting QuidelOrtho in addressing menu gaps and increasing competitiveness in international markets.
- Innovation Strategy Advancement: QuidelOrtho executives noted that this partnership will expedite the introduction of scalable testing solutions, further advancing their long-term innovation strategy in core growth markets while meeting customer demands for assay breadth and cost efficiency.
See More
QuidelOrtho Signs Strategic Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has signed a long-term supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitive position in the market.
- Market Expansion Initiative: This agreement will accelerate customer access to high-quality, scalable, and cost-effective solutions in select international markets outside the United States, addressing global demand.
- Product Diversification: By adding new analytical platforms and assay menus, QuidelOrtho will better serve key international markets, enhancing the adaptability of its products.
- Long-term Strategic Positioning: This collaboration not only strengthens QuidelOrtho's global market presence but also lays the groundwork for future growth, expected to drive the company's further development in international markets.
See More
QuidelOrtho Partners with Lifotronic for Global Expansion
- Strategic Partnership: QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitiveness in international markets.
- Market Expansion Initiative: This agreement aims to accelerate customer access to scalable, high-quality, and cost-effective solutions outside the United States, which is expected to significantly increase the company's market penetration globally.
- Product Portfolio Enhancement: By collaborating with Lifotronic, QuidelOrtho will be able to add new analytical platforms and assay menus, catering to diverse market needs and thereby enhancing product diversity and market adaptability.
- International Market Strategy: This partnership not only reinforces QuidelOrtho's global strategy but also aims to drive business growth in key international markets, thereby increasing the company's influence in the global medical testing sector.
See More
QuidelOrtho Enters Strategic Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has signed a long-term strategic supply agreement with Lifotronic to expand its global immunoassay portfolio, introducing new analyzer platforms to enhance market competitiveness.
- Market Expansion Initiative: This agreement will accelerate QuidelOrtho's customer access in key international markets outside the U.S., providing high-quality, cost-effective solutions to meet the growing global demand for testing.
- Portfolio Enrichment: By adding new analyzer platforms and expanding the assay menu, QuidelOrtho will be able to offer a broader range of testing options, thereby enhancing its service capabilities and customer satisfaction in the global market.
- Long-term Strategic Implications: This collaboration not only aids QuidelOrtho's positioning in international markets but also strengthens its leadership in the global immunodiagnostics sector, further solidifying its market share.
See More
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitive position in the market.
- International Market Expansion: This agreement will accelerate QuidelOrtho's customer access outside the United States, ensuring the provision of scalable, high-quality, and cost-effective solutions to meet the growing global demand for testing.
- Product Portfolio Enhancement: Through collaboration with Lifotronic, QuidelOrtho will introduce new analyzer platforms and assay menus, further increasing its product diversity and service capabilities in international markets.
- Market Influence Growth: This initiative not only aids QuidelOrtho in penetrating key international markets but also enhances its market share and brand influence in the global immunodiagnostics sector.
See More
QuidelOrtho Enters Long-Term Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has signed a long-term supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, enhancing its competitive position in the market.
- Market Expansion Initiative: This agreement will accelerate QuidelOrtho's customer access in markets outside the U.S., providing high-quality, scalable, and cost-effective solutions to meet global demand.
- Product Line Enhancement: By collaborating with Lifotronic, QuidelOrtho will introduce new analytical platforms, further increasing its product diversity and technological edge in international markets.
- Future Growth Potential: This move not only helps boost QuidelOrtho's market share but also lays the groundwork for long-term growth in the global immunoassay sector, reflecting the company's commitment to international markets.
See More
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic
- Strategic Supply Agreement: QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic to expand its global immunoassay portfolio, aiming to accelerate customer access to high-quality, cost-effective solutions in international markets.
- New Assay Additions: The collaboration is expected to add over 25 new assays to QuidelOrtho's menu, enhancing its competitiveness in international tenders and catering to diverse needs from small laboratories to large high-throughput environments.
- Market Expansion Focus: The commercial focus of the agreement will be on multiple regions including Europe, the Middle East, Africa, and Asia-Pacific, supporting QuidelOrtho in addressing menu gaps and increasing competitiveness in international markets.
- Innovation Strategy Advancement: QuidelOrtho executives noted that this partnership will expedite the introduction of scalable testing solutions, further advancing their long-term innovation strategy in core growth markets while meeting customer demands for assay breadth and cost efficiency.
See More
